This inventor holds 3 USPTO granted patents and 3 EPO patents. Top assignees: Cheiljedang Corp., Cj Cheiljedang Corporation. Active years: 2006-2011.
Company Filing History:
Years Active: 2006-2011
Title: Innovations of Dong-Eok Lee
Introduction
Dong-Eok Lee is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of fusion proteins. With a total of 3 patents to his name, Lee's work has the potential to impact medical treatments significantly.
Latest Patents
One of his latest patents is a fusion protein that enhances the in vivo activity of erythropoietin. This invention involves a fusion of the carboxy terminal of human erythropoietin (EPO) with a peptide fragment from the β subunit of human chorionic gonadotropin (HCG). The result is a fusion protein that exhibits improved activity in vivo. Another notable patent is a fusion protein that also enhances the in vivo activity of erythropoietin, where a carboxy terminal peptide fragment of thrombopoietin is fused with the carboxy terminal of human erythropoietin. This innovation boasts a significantly enhanced in vivo half-life due to increased carbohydrate content, while maintaining the inherent activity of erythropoietin and avoiding antigenicity when applied to the human body.
Career Highlights
Throughout his career, Dong-Eok Lee has worked with notable companies such as Cheiljedang Corporation and CJ Cheiljedang Corporation. His experience in these organizations has contributed to his expertise in biotechnology and protein engineering.
Collaborations
Lee has collaborated with several professionals in his field, including Ki-Wan Kim and Ji-Sook Park. These collaborations have likely enriched his research and development efforts.
Conclusion
Dong-Eok Lee's innovative work in the field of fusion proteins demonstrates his commitment to advancing biotechnology. His patents reflect a deep understanding of protein interactions and their potential applications in medicine.